Theralogix reports record 2025 growth, leadership changes, and new science-backed supplement launches for 2026.

Theralogix, a Maryland-based supplement company, reported record 2025 results with 25% growth in revenue and profit, its strongest performance in 23 years. Founding CEO Jay Hammer is stepping down to become CEO Emeritus, succeeded by Andreas Wolf, former CEO of EyePromise/ZeaVision. Christopher Good, COO for over 15 years, is promoted to President. The company plans to launch new products in 2026—OvaNAD+™, AgeRx™, TreBiome™, and Androsyn™—focused on reproductive health, longevity, gut health, and testosterone support. Theralogix continues to emphasize science-backed formulations, third-party testing by NSF® International, and physician recommendations.